Advertisement
UK markets close in 8 hours 27 minutes
  • FTSE 100

    8,023.87
    0.00 (0.00%)
     
  • FTSE 250

    19,599.39
    0.00 (0.00%)
     
  • AIM

    749.18
    0.00 (0.00%)
     
  • GBP/EUR

    1.1592
    +0.0004 (+0.03%)
     
  • GBP/USD

    1.2344
    -0.0006 (-0.05%)
     
  • Bitcoin GBP

    53,815.65
    +20.24 (+0.04%)
     
  • CMC Crypto 200

    1,402.16
    -12.60 (-0.89%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,315.20
    -31.20 (-1.33%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,786.30
    +274.61 (+1.66%)
     
  • DAX

    17,860.80
    +123.44 (+0.70%)
     
  • CAC 40

    8,040.36
    +17.95 (+0.22%)
     

How Eli Lilly Is Thinning Out the Competition

Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.